RT Journal Article
SR Electronic
T1 Pulmonary renal syndrome: a clinical review
JF Breathe
JO Breathe
FD European Respiratory Society
SP 220208
DO 10.1183/20734735.0208-2022
VO 18
IS 4
A1 Niamh Boyle
A1 Marissa O'Callaghan
A1 Ali Ataya
A1 Nishant Gupta
A1 Michael P. Keane
A1 David J. Murphy
A1 Cormac McCarthy
YR 2022
UL http://breathe.ersjournals.com/content/18/4/220208.abstract
AB The term “pulmonary renal syndrome” describes a clinical syndrome which is characterised by the presence of both diffuse alveolar haemorrhage and glomerulonephritis. It encompasses a group of diseases with distinctive clinical and radiological manifestations, as well as different pathophysiological processes. The most common diseases implicated are anti-neutrophil cytoplasm antibodies (ANCA)-positive small vessel vasculitis and anti-glomerular basement membrane (anti-GBM) disease. Prompt recognition is required as respiratory failure and end-stage renal failure can rapidly occur. Treatment includes a combination of glucocorticoids, immunosuppression, plasmapheresis and supportive measures. The use of targeted treatments has significantly reduced mortality. Thus, an understanding of pulmonary renal syndrome is essential for the respiratory physician.Pulmonary renal syndrome is the combination of rapidly progressive glomerulonephritis (RPGN) and diffuse alveolar haemorrhage (DAH). Morbidity and mortality are high so prompt diagnosis and intervention are key for the respiratory physician. https://bit.ly/3UFAmR9